LDS/Medical Tests/Barrett's-Associated Neoplasia, Cytology

Barrett's-Associated Neoplasia, Cytology

Barrett’s esophagus (BE) is a premalignant condition in which the normal stratified squamous epithelium of the distal esophagus is replaced by columnar epithelium, most often as a consequence of chronic gastroesophageal reflux disease (GERD). It predominantly affects middle-aged to older adults and is more common in males, individuals with central obesity, tobacco use, and chronic GERD. BE is clinically significant because it represents the principal precursor lesion to esophageal adenocarcinoma (EAC), an aggressive malignancy with rising incidence and poor prognosis when diagnosed at advanced stages.

The diagnosis of BE is established endoscopically and confirmed histologically by the presence of intestinal metaplasia with goblet cells, although diagnostic criteria may vary among guidelines. Dysplasia is the strongest histologic predictor of progression to carcinoma but is subject to sampling limitations and interobserver variability, particularly in cases classified as indefinite for dysplasia or low-grade dysplasia.

Barrett’s-associated neoplasia follows a stepwise progression from metaplasia to low-grade dysplasia, high-grade dysplasia, and invasive adenocarcinoma. Early identification of dysplastic or neoplastic changes is critical, as endoscopic eradication therapies are effective in preventing progression when disease is detected at an early stage.

Cytologic evaluation of esophageal samples, typically obtained by endoscopic brushings, provides a minimally invasive adjunct to histologic biopsy. Cytology allows assessment of cellular atypia, nuclear abnormalities, architectural disorganization, and features suggestive of dysplasia or malignancy. Liquid-based cytology preparations improve specimen adequacy and cellular preservation and may be combined with ancillary studies when indicated. Cytology is particularly useful when biopsy material is limited, when histologic findings are equivocal, or as part of surveillance strategies aimed at identifying patients who require closer endoscopic follow-up.

  • Adjunctive tool for detection of dysplasia or neoplasia in patients with Barrett’s esophagus
  • Assists in early identification of Barrett’s-associated adenocarcinoma in high-risk patients
  • Useful when histologic biopsy results are indeterminate or limited by sampling
  • Supports surveillance and triage decisions, including need for repeat endoscopy or targeted biopsy
A positive cytology result demonstrates cellular features consistent with high-grade dysplasia or malignancy and warrants prompt correlation with histologic biopsy and endoscopic findings. These patients typically require intensified surveillance or therapeutic intervention. Atypical or suspicious cytology results indicate cellular abnormalities that are insufficient for definitive diagnosis but raise concern for dysplasia. Correlation with histology, repeat sampling, or closer clinical follow-up is recommended. A negative cytology result shows no cytologic evidence of dysplasia or malignancy. This finding is associated with lower short-term risk but does not exclude the presence of focal dysplasia or early neoplasia. Clinical correlation and continued surveillance remain essential.

Negative for dysplasia or malignant cells

Cytologic examination of esophageal samples using liquid-based preparation or direct smear, with Papanicolaou staining.

Esophageal cytology brushings

Samples should be placed in appropriate cytology fixative or transport medium and submitted promptly to the laboratory.

Stability

Room temperature: stable in fixative according to manufacturer specifications

Frozen samples: not acceptable

EsoGuard Methylation Assay for Barrett’s esophagus, esophageal biopsy, immunocytochemistry on cell block preparations, molecular assays when indicated, complete blood count, comprehensive metabolic panel.
2 to 5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login